Cinacalcet
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Cinacalcet and local guidelines before prescribing.
Mechanism
Calcimimetic increasing parathyroid calcium-sensing receptor sensitivity.
Uses
Secondary hyperparathyroidism in dialysis, primary hyperparathyroidism when surgery unsuitable, parathyroid carcinoma.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hypocalcaemia, nausea, vomiting, QT prolongation.
Interactions
CYP3A4 and 2D6 interactions.
Contraindications and cautions
Hypocalcaemia
Monitoring
Calcium, PTH, ECG
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Caution in severe hepatic impairment
Overdose and reversal
Supportive; calcium
Special advice
Check calcium within one week of starting or changing dose.
More from the textbook: uses, cautions and other points
- Cinacalcet - calcimimetic (makes the parathyroid more sensitive to calcium → less PTH); secondary hyperparathyroidism on dialysis, parathyroid cancer, primary hyperparathyroidism when surgery isn't possible; hypocalcaemia, nausea.
Endocrine: Anatomy Physiology and Pharmacology - Cinacalcet | Calcimimetic; secondary hyperparathyroidism in dialysis; hypocalcaemia.
Endocrine: Anatomy Physiology and Pharmacology - Cinacalcet (calcimimetic): For parathyroid carcinoma, or for primary hyperparathyroidism when surgery is not possible.
Endocrinology: Bone Medicine - Cinacalcet if calcium remains high and surgery is not possible.
Endocrinology: Bone Medicine - Drugs - denosumab , IV bisphosphonates, PPIs (via low magnesium), foscarnet, cinacalcet.
Endocrinology: Bone Medicine - Cinacalcet: For refractory secondary hyperparathyroidism on dialysis (NICE TA117 criteria).
Endocrinology: Bone Medicine - Cinacalcet | Calcimimetic for primary hyperparathyroidism when surgery is not possible, parathyroid carcinoma, and refractory secondary hyperparathyroidism on dialysis. Risk of nausea and hypocalcaemia.
Endocrinology: Bone Medicine - Calcimimetics - cinacalcet (oral) or etelcalcetide (IV after dialysis) - make the parathyroid more sensitive to calcium → lower PTH; for secondary hyperparathyroidism on dialysis; low calcium , nausea. Parathyroidectomy if severe or tertiary.
Renal: Anatomy, Physiology and Pharmacology
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (2 mentions)
- Endocrinology: Bone Medicine (5 mentions)
- Renal: Anatomy, Physiology and Pharmacology (2 mentions)
- Renal: Chronic Kidney Disease (2 mentions)
- Renal: Dialysis and Transplant (2 mentions)
- Surgey: Breast and endocrine surgery (2 mentions)
- Acute Medicine: Electrolytes, acid–base, AKI and metabolic emergencies (2 mentions)